Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regulus Therapeutics names new board member
Mr Papadopoulos will complement Regulus Therapeutics’s board of directors, which is comprised of industry leaders in drug discovery and development. Mr Papadopoulos retired as vice chairman of Cowen
Mr Papadopoulos will complement Regulus Therapeutics’s board of directors, which is comprised of industry leaders in drug discovery and development. Mr Papadopoulos retired as vice chairman of Cowen
The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different
These represent market opportunities potentially exceeding $600 million in annual revenue for Abraxis. The transaction includes an initial strategic investment, by Abraxis, in ProMetic of $7 million at
So far, the complete set of optimized synthetic human genes sold via Qiagen’s web portal GeneGlobe (QIAgenes) was designed for the production in E coli bacteria only. The
Mr Killin replaces Eugene Bomba, who will be leaving his position as CFO of the company to return to private practice. Justin Belobaba, president and CEO of Healthscreen,
CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes. Afluria is indicated for
In this position, Dr Trave will expand Premier Research’s capabilities in the area of drug development consulting and strengthen capabilities in the oncology therapeutic area. Dr Trave will
This acquisition will strengthen Wolters Kluwer Health’s portfolio in the growing point of care and electronic medical record markets by expanding its product and services offerings. The transaction
The Rayhack System consists of procedure-specific bone-cutting guides and fixation plates that allow precise shortening and repositioning of the radius and ulna, the two major bones of the
Nanobodies are a new class of therapeutic proteins that contain the unique structural and functional properties of naturally occurring single domain antibodies. The partners will collaborate to research